Clinical Trials Logo

Childhood Asthma clinical trials

View clinical trials related to Childhood Asthma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05105386 Not yet recruiting - Clinical trials for Environmental Exposure

The Impact of Synergies of Indoor Air Pollutants on Childhood Health and Wellbeing

SynAir-Child
Start date: September 2023
Phase:
Study type: Observational [Patient Registry]

To quantify health effects of synergizing chemical and biological pollutants in a targeted population setting, i.e., school-aged children. Indoor air pollutants will be monitored within the classrooms with high end sensors. Exposure data from additional sources (outdoor, home, transports) will be obtained. Health outcomes will be assessed prospectively using validated medical procedures and real-time tracking with mobile health (mHealth) equipment and a gamified computer app.

NCT ID: NCT02678949 Not yet recruiting - Childhood Asthma Clinical Trials

Changes in the Lung Clearance Index in Pediatric Patients With Asthma

Start date: March 2016
Phase: N/A
Study type: Interventional

The multiple breath washout (MBW) is one of pulmonary function test that displays flow and gas concentration plotted against time, and shows an exponential decay in end-tidal gas concentration (washout curve). A number of of indices to describe the washout curve have been proposed, the most commonly reported is the Lung Clearance Index (LCI). This is a simple measure of ventilation heterogeneity derived from MBW, that can be used after challenge with a short action bronchodilator and in response to inhaled steroids, both in the conductive airways as acinar. Patients with moderate and severe asthma are characterized by an abnormality in both, conductive and the acinar airway. Therefore the following research question could be: what are the abnormalities in the heterogeneity of ventilation in children with mild and moderate asthma, with respect to the healthy population measured by MBW, and whether these alterations persist after challenge with inhaled steroids and B2 agonists short-acting.